Know Cancer

forgot password

A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects With Metastatic Gastric Cancer

Phase 2
18 Years
Not Enrolling
Neoplasms, Gastrointestinal Tract

Thank you

Trial Information

A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects With Metastatic Gastric Cancer

Inclusion Criteria:

- histologically confirmed diagnosis of advanced or metastatic gastric carcinoma, or
adenocarcinoma of the gastroesophageal junction or of the distal esophagus. Subjects
with tumors of the gastroesophageal junction or of the distal esophagus may be
eligible provided that the tumor is not of squamous or sarcomatous histology

- Measurable disease

- The subject consents to provide paired tumor biopsies, directly prior to commencing
study treatment and then between Days 5 and 8.

- The subject has an ECOG performance status ≤2.

- The subject is able to ingest the GSK1363089 capsules.

- In the adrenocorticotropic hormone (ACTH) stimulation test, the subject has a serum
cortisol level ≥20 μg/dL (552 nmol/L) 30-90 minutes after injection of ACTH.

- The subject has liver, kidney and marrow function.

- The subject is capable of understanding and complying with the protocol and has
signed the informed consent document.

- Sexually active subjects (male and female) must use a medically-accepted method of
contraception during the course of the study.

- Female subjects of childbearing potential must have a negative serum pregnancy test
at screening.

- The subject has had no other diagnosis of malignancy (unless non-melanoma skin cancer
or a malignancy diagnosed ≥5 years ago, and has no evidence of disease for 5 years
prior to the screening for this study).

- QTc < 470 msec.

Exclusion Criteria:

- The subject has received more than two lines of prior cytotoxic chemotherapy for
locally advanced or metastatic disease. For the purpose of this protocol, neoadjuvant
therapy would not be considered to be prior cytotoxic chemotherapy. In addition,
potential subjects who have received prior treatment with c-MET signaling inhibitor
are excluded.

- The subject has received an investigational drug within 14 days of the first dose of
study drug.

- The subject has received chemotherapy, immunotherapy, or radiation therapy (to

≥25% of his or her bone marrow) within 14 days or has received nitrosoureas or
mitomycin C within 6 weeks prior to the scheduled first dose of GSK1363089.

- The subject has AEs due to investigational drugs or other medications administered
more than 21 days prior to enrollment that have not recovered to Grade ≤1 using NCI
CTCAE v3.0, with the exception of alopecia greater than grade 1.

- The subject has known brain metastases.

- The subject has uncontrolled intercurrent illness including, but not limited to,
ongoing or active infection, symptomatic congestive heart failure, unstable angina
pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
limit compliance with study requirements.

- The subject is pregnant or breastfeeding.

- The subject is known to be positive for the human immunodeficiency virus (HIV).

- The subject has a previously identified allergy or hypersensitivity to components of
the GSK1363089 formulation.

- The subject is unable or unwilling to abide by the study protocol or cooperate fully
with the investigator or designee.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective response rate (RECIST) of GSK1363089 on 2 different dosing regimens

Outcome Time Frame:

4 months (average)

Safety Issue:


Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

March 2007

Completion Date:

November 2009

Related Keywords:

  • Neoplasms, Gastrointestinal Tract
  • c-Met
  • Metastatic Gastric Carcinoma
  • adenocarcinoma
  • Gastric cancer
  • GSK1363089
  • XL880
  • MET inhibitor
  • Neoplasms
  • Digestive System Neoplasms
  • Gastrointestinal Neoplasms
  • Stomach Neoplasms



GSK Investigational Site Phoenix, Arizona  85013 - 4496
GSK Investigational Site Bakersfield, California  93309
GSK Investigational Site Springfield, Massachusetts  01107
GSK Investigational Site St. Louis, Montana  63110
GSK Investigational Site Albuquerque, New Mexico  87109
GSK Investigational Site Raleigh, North Carolina  27609
GSK Investigational Site Fort Worth, Texas  76104
GSK Investigational Site Green Bay, Wisconsin  54301
GSK Investigational Site Savannah, Georgia  31405
GSK Investigational Site Park Ridge, Illinois  60068
GSK Investigational Site Royal Oak, Michigan  48073
GSK Investigational Site New York, New York  10021
GSK Investigational Site Birmingham, Alabama  35209
GSK Investigational Site Washington, District of Columbia  20307-5001
GSK Investigational Site Oregon City, Oregon  97045